Allogeneic transplantation for myelodysplastic syndrome (MDS)

Blood Reviews

Volumn 21, Issue 2, 2007, Pages 61-71

  Ingram, Wendy ^a   Lim, Zi Yi ^a   Mufti, Ghulam J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Allogeneic Stem Cell Transplantation; Myelodysplastic Syndrome

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ALLOTRANSPLANTATION; ARTICLE; CELLULAR IMMUNITY; DONOR LYMPHOCYTE INFUSION; DYSPLASIA; GRAFT DYSFUNCTION; GRAFT VERSUS HOST REACTION; HEALTH CENTER; HLA SYSTEM; HUMAN; IMMUNOLOGY; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SIBLING; T CELL DEPLETION; UMBILICAL CORD BLOOD; VOLUNTEER;

DONOR SELECTION; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LEUKOCYTE TRANSFUSION; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 33947247435     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2006.03.003     Document Type: Article

References (90)

1. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
2. Jaffe E.H.N., Stein H., and Vardiman J. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC (2001)
3. Mufti G.J., Stevens J.R., Oscier D.G., Hamblin T.J., and Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59 (1985) 425-433
4. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
5. Mijovic A.D.M., Sekhavat M., Czepulowski B., and Mufti G.J. Do Patients with Low-grade Myelodysplastic Syndrome Mobilise Normal Hemopoietic Progenitors?. Leukaemia Research 25 (2001) S1-S22
6. Carella A.M., Dejana A., Lerma E., et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol 95 (1996) 127-130
7. De Witte T., Van Biezen A., Hermans J., et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood 90 (1997) 3853-3857
8. Laporte J.P., Isnard F., Lesage S., et al. Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study. Leukemia 7 (1993) 2030-2033
9. Bensinger W.I. Should we purge?. Bone Marrow Transplant 21 (1998) 113-115
10. Runde V., de Witte T., Arnold R., et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21 (1998) 255-261
11. Sierra J., Perez W.S., Rozman C., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100 (2002) 1997-2004
12. Arnold R., de Witte T., van Biezen A., et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 21 (1998) 1213-1216
13. de Witte T., Hermans J., Vossen J., et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110 (2000) 620-630
14. Anderson J.E., Appelbaum F.R., Fisher L.D., et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82 (1993) 677-681
15. Anderson J.E., Appelbaum F.R., and Storb R. An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk Lymphoma 17 (1995) 95-99
16. Anderson J.E., Appelbaum F.R., Schoch G., et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 87 (1996) 51-58
17. Anderson J.E., Appelbaum F.R., Schoch G., et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14 (1996) 220-226
18. Deeg H.J., and Appelbaum F.R. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Leuk Res 24 (2000) 653-663
19. Castro-Malaspina H., Harris R.E., Gajewski J., et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99 (2002) 1943-1951
20. Anderson J.E., Anasetti C., Appelbaum F.R., et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 93 (1996) 59-67
21. Jacobs R.H., Cornbleet M.A., Vardiman J.W., Larson R.A., Le Beau M.M., and Rowley J.D. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 67 (1986) 1765-1772
22. Tricot G., Boogaerts M.A., De Wolf-Peeters C., Van den Berghe H., and Verwilghen R.L. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br J Haematol 59 (1985) 659-670
23. Toyama K., Ohyashiki K., Yoshida Y., et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 7 (1993) 499-508
24. Morel P., Hebbar M., Lai J.L., et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7 (1993) 1315-1323
25. Nevill T.J., Fung H.C., Shepherd J.D., et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92 (1998) 1910-1917
26. Sutton L., Chastang C., Ribaud P., et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 88 (1996) 358-365
27. Copelan E.A., Penza S.L., Elder P.J., et al. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation. Bone Marrow Transplant 25 (2000) 1219-1222
28. Yakoub-Agha I., de La Salmoniere P., Ribaud P., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 18 (2000) 963-971
29. Deeg H.J., Shulman H.M., Anderson J.E., et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95 (2000) 1188-1194
30. Du W., Dansey R., Abella E.M., et al. Successful allogeneic bone marrow transplantation in selected patients over 50 years of age-a single institution's experience. Bone Marrow Transplant 21 (1998) 1043-1047
31. Parker J.E., Shafi T., Pagliuca A., et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 119 (2002) 144-154
32. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351 (2004) 2276-2285
33. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351 (2004) 2265-2275
34. Laughlin M.J., Barker J., Bambach B., et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 344 (2001) 1815-1822
35. Sanz G.F., Saavedra S., Planelles D., et al. Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood 98 (2001) 2332-2338
36. Davies S.M., Ruggieri L., DeFor T., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100 (2002) 3825-3827
37. Rubinstein P., and Stevens C.E. Placental blood for bone marrow replacement: the New York Blood Center's program and clinical results. Baillieres Best Pract Res Clin Haematol 13 (2000) 565-584
38. Ooi J., Iseki T., Takahashi S., et al. Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia. Blood 103 (2004) 489-491
39. Long G.D., Laughlin M., Madan B., et al. Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant 9 (2003) 772-780
40. Barker J.N., Weisdorf D.J., DeFor T.E., Blazar B.R., Miller J.S., and Wagner J.E. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102 (2003) 1915-1919
41. Nevill T.J., Shepherd J.D., Reece D.E., et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 10 (1992) 445-450
42. Ratanatharathorn V., Karanes C., Uberti J., et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 81 (1993) 2194-2199
43. O'Donnell M.R., Long G.D., Parker P.M., et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 13 (1995) 2973-2979
44. De Witte T., Zwaan F., Hermans J., et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74 (1990) 151-155
45. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002) 1201-1207
46. Scott B., Deeg H.J., Storer B., et al. Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. Leuk Lymphoma 45 (2004) 2409-2417
47. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 35 (2005) 225-231
48. Remberger M., Storer B., Ringden O., and Anasetti C. Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 29 (2002) 391-397
49. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
50. Ferrara J.L., and Deeg H.J. Graft-versus-host disease. N Engl J Med 324 (1991) 667-674
51. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 (1999) 412-415
52. Barrett A.J., Rezvani K., Solomon S., et al. New developments in allotransplant immunology. Hematology (Am Soc Hematol Educ Program) (2003) 350-371
53. Klangsinsirikul P., Carter G.I., Byrne J.L., Hale G., and Russell N.H. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 99 (2002) 2586-2591
54. Morris E.C., Rebello P., Thomson K.J., et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 102 (2003) 404-406
55. Waller E.K., Langston A.A., Lonial S., et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 9 (2003) 460-471
56. Ho A.Y., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukaemia with multilineage dysplasia using Fludarabine, Busulphan and Alemtuzumab (CAMPATH-1H)(FBC) conditioning. Blood (2004)
57. Perez-Simon J.A., Kottaridis P.D., Martino R., et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100 (2002) 3121-3127
58. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96 (2000) 2419-2425
59. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
60. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
61. Malladi R.K., Peniket A.J., Norton A.E., et al. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies. Eur J Haematol 73 (2004) 85-92
62. Raiola A.M., Van Lint M.T., Lamparelli T., et al. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol 109 (2000) 716-721
63. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 (2001) 631-637
64. Bornhauser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102 (2003) 820-826
65. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
66. Couban S., Simpson D.R., Barnett M.J., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100 (2002) 1525-1531
67. Nivison-Smith I., Bradstock K.F., Szer J., et al. Allogeneic haemopoietic cell transplants in Australia, 1996-a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow. Bone Marrow Transplant 28 (2001) 21-27
68. Parreira A., Smith J., Hows J.M., et al. Immunological reconstitution after bone marrow transplant with Campath-1 treated bone marrow. Clin Exp Immunol 67 (1987) 142-150
69. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99 (2002) 4357-4363
70. Chakrabarti S., Avivi I., Mackinnon S., et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol 119 (2002) 1125-1132
71. Chakrabarti S., Mautner V., Osman H., et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100 (2002) 1619-1627
72. Sullivan K.M., Storb R., Buckner C.D., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320 (1989) 828-834
73. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86 (1995) 2041-2050
74. Depil S., Deconinck E., Milpied N., et al. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant 33 (2004) 531-534
75. Shiobara S., Nakao S., Ueda M., et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 26 (2000) 769-774
76. de Lima M., Bonamino M., Vasconcelos Z., et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 27 (2001) 73-78
77. Taylor P.A., Lees C.J., and Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99 (2002) 3493-3499
78. Michalek J., Collins R.H., Durrani H.P., et al. Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci U S A 100 (2003) 1180-1184
79. Marijt W.A., Heemskerk M.H., Kloosterboer F.M., et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A 100 (2003) 2742-2747
80. Michalek J., Collins R.H., Hill B.J., Brenchley J.M., and Douek D.C. Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation. Lancet 361 (2003) 1183-1185
81. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94 (1999) 333-339
82. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
83. Klingemann H.G. Natural killer cell-based immunotherapeutic strategies. Cytotherapy 7 (2005) 16-22
84. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005) 3051-3057
85. Gong J., Chen D., Kashiwaba M., and Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3 (1997) 558-561
86. Gong J., Koido S., Kato Y., et al. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res 28 (2004) 1303-1312
87. Darling D., Galea-Lauri J., Gaken J., et al. In vitro immune modulation by antibodies coupled to tumour cells. Gene Ther 4 (1997) 1350-1360
88. Hirst W.J., Buggins A., Darling D., Gaken J., Farzaneh F., and Mufti G.J. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1. Gene Ther 4 (1997) 691-699
89. Buggins A.G., Lea N., Gaken J., et al. Effect of costimulation and the microenvironment on antigen presentation by leukemic cells. Blood 94 (1999) 3479-3490
90. Chan L., Hardwick N., Darling D., et al. IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol Ther 11 (2005) 120-131